Market Overview

BridgeBio Pharma Opens Above IPO Price

BridgeBio Pharma Opens Above IPO Price

BridgeBio Pharma (NASDAQ: BBIO) made its public debut Thursday morning, opening at $30.61 after being priced at $17 per share.

JPMorgan, Goldman Sachs, Jefferies, SVB Leerink, KKR, Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James are the underwriters for the offering.

BridgeBio Pharma was founded in 2015 and headquartered in Palo Alto, California. The company focuses on identifying and advancing transformative medicines to treat diseases that arise from defects in a single gene, and for cancers with clear genetic drivers.

Its pipeline consists of over 15 development programs that are evaluating product candidates in early discovery to late-stage development.

The stock traded around $30 per share at time of publication.

Related Links:

BridgeBio Pharma IPO: What You Need To Know

Pfizer Receives European Commission Approval For Breast Cancer Drug TALZENNA


Related Articles (BBIO)

View Comments and Join the Discussion!

Posted-In: Biotech News IPOs General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at